How many stocks are there of Theraclion?
The current number of stocks of Theraclion is 45.94 M undefined.
Theraclion Stocks 2024
Theraclion Stocks
45.94 M
Ticker
ALTHE.PA
ISIN
FR0010120402
WKN
A112C8
In 2024, Theraclion had 45.94 M outstanding stocks, a 0% change from the 45.94 M stocks in the previous year.
The Theraclion Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2025e | 45.94 |
| 2024e | 45.94 |
| 2023 | 45.94 |
| 2022 | 29.39 |
| 2021 | 22.77 |
| 2020 | 16.18 |
| 2019 | 15.25 |
| 2018 | 8.44 |
| 2017 | 7.49 |
| 2016 | 5.26 |
| 2015 | 4.26 |
| 2014 | 3.67 |
| 2013 | 2.99 |
| 2012 | 0.75 |
| 2011 | 0.64 |
| 2010 | 0.6 |
Theraclion shares outstanding FR0010120402 · A112C8
The number of shares was Theraclion in 2023 — This indicates how many shares 45.938 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Theraclion earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Theraclion's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Theraclion’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Theraclion's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2010 | 600,000 Aktien |
| 2011 | 640,000 Aktien |
| 2012 | 750,000 Aktien |
| 2013 | 2.99 M Aktien |
| 2014 | 3.67 M Aktien |
| 2015 | 4.26 M Aktien |
| 2016 | 5.26 M Aktien |
| 2017 | 7.49 M Aktien |
| 2018 | 8.44 M Aktien |
| 2019 | 15.25 M Aktien |
| 2020 | 16.18 M Aktien |
| 2021 | 22.77 M Aktien |
| 2022 | 29.39 M Aktien |
| 2023 | 45.94 M Aktien |
| 2024e | 45.94 M Aktien |
| 2025e | 45.94 M Aktien |
Theraclion Aktienanalyse
What does Theraclion do?
Theraclion SA is a French medical company specializing in the development and production of innovative therapy systems. The company was founded in 2004 and is headquartered in Malakoff, France. Theraclion's business model is based on the development and marketing of medical devices based on High Intensity Focused Ultrasound (HIFU) technology. This technology uses ultrasound pulses to treat targeted areas in the body without the need for surgical intervention. Theraclion specializes in three main areas: oncology, dermatology, and aesthetics. In the field of oncology, Theraclion has developed the Echopulse system, which is used for the treatment of breast tumors. The system applies high-intensity ultrasound pulses to kill tumor cells without damaging surrounding tissue. This non-invasive method of tumor treatment is very promising and has already shown promising results in several studies. In the field of dermatology, Theraclion has developed the Echovist system, which is used for the treatment of nevi (moles). The system also utilizes HIFU technology to destroy the nevi, resulting in a significant improvement in the aesthetic appearance of the skin. In the field of aesthetics, Theraclion has developed the Sonovein system, which is used for the treatment of varicose veins. The system also utilizes HIFU technology to close the veins and thus improve the patient's appearance and quality of life. Theraclion has experienced impressive growth in recent years and is now an important player in the medical industry. The company has filed several patents and works closely with leading doctors and research institutions to maximize the effectiveness of its products. Overall, Theraclion aims to offer innovative therapies that meet the needs of patients and help them lead fulfilling lives. The company is committed to continuously improving its products and services and strives to achieve even greater successes in the future. Theraclion ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Theraclion's Shares Outstanding
Theraclion's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Theraclion’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Theraclion’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Theraclion’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Theraclion stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Theraclion are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Theraclion evolved in recent years?
The number of shares of Theraclion has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Theraclion as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Theraclion?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Theraclion pay?
Over the past 12 months, Theraclion paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theraclion is expected to pay a dividend of 0 EUR.
What is the dividend yield of Theraclion?
The current dividend yield of Theraclion is .
When does Theraclion pay dividends?
Theraclion pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Theraclion?
Theraclion paid dividends every year for the past 0 years.
What is the dividend of Theraclion?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Theraclion located?
Theraclion is assigned to the 'Health' sector.
Wann musste ich die Aktien von Theraclion kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Theraclion from 9/29/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.
When did Theraclion pay the last dividend?
The last dividend was paid out on 9/29/2024.
What was the dividend of Theraclion in the year 2023?
In the year 2023, Theraclion distributed 0 EUR as dividends.
In which currency does Theraclion pay out the dividend?
The dividends of Theraclion are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Theraclion
Our stock analysis for Theraclion Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theraclion Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
